Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early

BackgroundGlioblastoma (GB) is the most severe form of brain cancer, with a 12-15 month median survival. Surgical resection, temozolomide (TMZ) treatment, and radiotherapy remain the primary therapeutic options for GB, and no new therapies have been introduced in recent years. This therapeutic stand...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Mariangela Morelli, Francesca Lessi, Serena Barachini, Romano Liotti, Nicola Montemurro, Paolo Perrini, Orazio Santo Santonocito, Carlo Gambacciani, Matija Snuderl, Francesco Pieri, Filippo Aquila, Azzurra Farnesi, Antonio Giuseppe Naccarato, Paolo Viacava, Francesco Cardarelli, Gianmarco Ferri, Paul Mulholland, Diego Ottaviani, Fabiola Paiar, Gaetano Liberti, Francesco Pasqualetti, Michele Menicagli, Paolo Aretini, Giovanni Signore, Sara Franceschi, Chiara Maria Mazzanti
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2022-09-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	glioblastoma metabolic imaging drug response assay predictive model FLIM (fluorescence lifetime imaging microscopy)
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fonc.2022.969812/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!